How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
Cytogen is also developing CYT-500, a therapeutic product candidate usingthe same monoclonal antibody from PROSTASCINT combined with a higher affinity linker to attach a therapeutic as opposed to an imaging radionuclide. CYT-500is designed to enable targeted delivery of a cytotoxic agent toPSMA-expressing cells. Cytogen expects to begin the first U.S. Phase Iclinical trial of CYT-500 in patients with hormone-refractory prostate cancer during 2006.
PROSTASCINT is indicated as a diagnostic imaging agent in newly diagnosedpatients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation and who are thought to be athigh risk for pelvic lymph node metastases. PROSTASCINT is also indicated asa diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is ahigh clinical suspicion of occult metastatic disease.
A copy of the full prescribing information for PROSTASCINT, including warnings, precautions, adverse events and other safety information, may beobtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the Web site at http://www.cytogen.com, which is not partof this press release.
PSMA is a protein abundantly expressed on the surface of prostate cancer cells, with an increased expression in high-grade cancers, metastatic diseaseand hormone-refractory prostate cancer. PSMA is also present at high levels onthe newly formed blood vessels, or neovasculature, needed for the growth and survival of many solid tumors. In contrast to other prostate-related antigenssuch as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP) and prostate secretory protein, PSMA is a membrane glycoprotein that is notsecreted. These unique attributes make PSMA an excellent target for monoclonalantibody diagnostic and therapeutic options in prostate and potentially othercancers. Clinical studies have also demonstrated that overexpression of PSMA determined by immunohistochemical staining using the 7E11.C5.3 antibody inprimary prostate cancer not only correlates with other adverse traditional prognostic factors, but can independently predict disease recurrence.
ABOUT CYTOGEN CORPORATION
Founded in 1980, Cytogen Corporation of Princeton, NJ , is a biopharmaceutical company dedicated to improving the lives of patients withcancer by acquiring, developing and commercializing innovative molecule stargeting the sites and stages of cancer progression. Cytogen's marketedproducts include QUADRAMET(R) (samarium Sm-153 lexidronam injection),PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution10mg/5mL) in the United States . Cytogen's development pipeline consists ofCYT-500, a therapeutic radiolabeled antibody targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostatecancer cells and the neovasculature of solid tumors. Cytogen also hasexclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) forall applications, and the exclusive right to market and sell ferumoxytol(previously Code 7228) for oncology applications in the United States . Fullprescribing information for the Company's products is available athttp://www.cytogen.com or by calling 800-833-3533. For more information,please visit the Company's website at http://www.cytogen.com, which is notpart of this press release.